CLINICAL TRIALS PROFILE FOR SALAGEN

All Clinical Trials for Salagen

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	CancerCare Manitoba	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	Jewish General Hospital	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	Newfoundland Cancer Treatment & Research Foundation	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	Notre-dame Hospital	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	Ottawa Hospital Research Institute	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	Alberta Health Services	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.

Clinical Trial Conditions for Salagen

Condition Name

Condition Name for Salagen
Intervention	Trials
Dry Mouth	4
Dry Eye	1
Head and Neck Cancer	1
Healthy Subjects	1

Condition MeSH

Condition MeSH for Salagen
Intervention	Trials
Xerostomia	5
Keratoconjunctivitis Sicca	1
Dry Eye Syndromes	1
Head and Neck Neoplasms	1

Clinical Trial Locations for Salagen

Trials by Country

Trials by Country for Salagen
Location	Trials
United States	4
Canada	1
Brazil	1
United Kingdom	1

Trials by US State

Trials by US State for Salagen
Location	Trials
Texas	4

Clinical Trial Progress for Salagen

Clinical Trial Phase

Clinical Trial Phase for Salagen
Clinical Trial Phase	Trials
Phase 3	2
Phase 1	1
N/A	4

Clinical Trial Status

Clinical Trial Status for Salagen
Clinical Trial Phase	Trials
Completed	7

Clinical Trial Sponsors for Salagen

Sponsor Name

Sponsor Name for Salagen
Sponsor	Trials
Roxane Laboratories	4
Alberta Health Services	1
Astellas Pharma Europe B.V.	1

Sponsor Type

Sponsor Type for Salagen
Sponsor	Trials
Other	7
Industry	5